Palvella Therapeutics, Inc. (PVLA)
NasdaqGM · USD · Healthcare · Biotechnology
$126.23 (+0.90%) as of
Key statistics
- Market cap
- 1.82B
- Forward P/E
- -15.82
- EPS (TTM)
- -4.85
- Dividend yield
- 0.00%
- 52-week range
- 68.96 – 161.38
- Profit margin
- 0.00%
- Analyst target
- $228.93
- Volume
- 109.51k
About Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Wayne, PA, United States
- Employees
- 29
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.